Yeztugo and the Future of HIV Prevention: How It Works and Why It Matters
In June 2025, U.S. regulators approved a medication that could dramatically change the fight against HIV. It’s called Yeztugo, and its active ingredient is lenacapavir. Some headlines have already called it a “100% effective HIV vaccine.” But behind the hype lies a more complex — and more interesting — reality.
Yeztugo is not a vaccine. It’s a new kind of long-acting preventive treatment that offers unprecedented protection. Its success rate in clinical trials was close to 100%, and it only needs to be injected twice a year.
But this is not a miracle shot. It’s a medical tool — powerful but precise — and to use it well, we need to understand how it works, what it can (and can’t) do, and who it’s for.
What Yeztugo Is — And Why It’s Different
Unlike vaccines, which stimulate the immune system to build long-term protection, Yeztugo (lenacapavir) is a direct-acting antiretroviral. Its role is to block HIV from infecting healthy cells in the first place. It doesn’t treat HIV. It doesn’t cure it. It simply prevents it — effectively and reliably.
Yeztugo is administered as a subcutaneous injection twice a year. After that, the drug stays active in the bloodstream for around six months, creating a protective barrier against the virus. This is a game-changer, especially compared to the traditional PrEP regimen, which requires taking a pill every single day.
How It Works — In Simple Terms
Lenacapavir belongs to a new class of drugs: capsid inhibitors. The “capsid” is the protective protein shell of HIV — the part that allows the virus to enter cells, release its RNA, and integrate into the human genome.
Yeztugo disrupts this process at multiple points:
- it prevents the capsid from uncoating, so the virus can’t activate inside the cell;
- it blocks the assembly of new viral particles, stopping reproduction;
- it causes premature breakdown of the virus, exposing it to the immune system before it can do damage.
In other words, Yeztugo neutralizes HIV before it ever gets a foothold.
What Clinical Trials Showed
The data behind Yeztugo is some of the strongest in HIV prevention history. Across the PURPOSE 1 and PURPOSE 2 trials (over 7,000 participants in total):
- In a trial group of women at high risk of infection, there were zero new HIV cases (2,134 participants).
- In the group of men who have sex with men and transgender individuals, there were only 2 infections among 2,179 participants.
- Side effects were minimal: mild pain at the injection site, occasional nausea — and nothing serious.
This makes Yeztugo the first HIV prevention method to combine near-perfect efficacy with only two injections per year — no pills, no daily compliance, no stigma.
Who Can Use It — And What to Keep in Mind
Yeztugo is designed only for people who are HIV-negative. A test is mandatory before the first dose. If given to someone with undiagnosed HIV, it could cause the virus to develop resistance — a dangerous complication.
Other key facts:
- It does not protect against other STIs (such as hepatitis or syphilis);
- It is not a cure or treatment for people already living with HIV;
- It does not replace condoms or other safe sex methods where broader protection is needed.
Relevant
Cost and Access
In the United States, the retail price is approximately \$28,000 per year — expensive, but still lower than lifelong HIV treatment. Gilead, the developer, has announced plans to:
- work with insurers and government programs to subsidize access;
- license generic versions of the drug in over 120 low- and middle-income countries;
- develop equity-based access models in partnership with national health systems.
The drug was approved by the FDA in June 2025. Rollout is expected in the U.S. by the end of the year, with international availability to follow in 2026.
Why It Matters
Yeztugo isn’t the end of HIV. But it might be the most practical tool we’ve ever had to stop it from spreading.
This treatment offers:
- greater protection for at-risk communities;
- an easier, lower-maintenance alternative to daily PrEP;
- the possibility of changing the HIV prevention model — from constant vigilance to simple, regular injections.
And most importantly, it works in silence — no reminders, no daily medication, no judgment.
There’s no magic cure for HIV — not yet. But Yeztugo is something real: a shift in how we think, plan, and protect.
It won’t solve every problem. But it’s a step forward — and for millions of people, maybe the one that counts most.
About the Author
